Home » Stocks » EXAS

Exact Sciences Corporation (EXAS)

Stock Price: $121.64 USD 0.62 (0.51%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
After-hours: $122.76 +1.12 (0.92%) Mar 5, 7:51 PM
Market Cap 20.57B
Revenue (ttm) 1.49B
Net Income (ttm) -848.53M
Shares Out 151.14M
EPS (ttm) -5.61
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $121.64
Previous Close $121.02
Change ($) 0.62
Change (%) 0.51%
Day's Open 121.33
Day's Range 110.12 - 123.00
Day's Volume 3,018,009
52-Week Range 35.25 - 159.54

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 week ago

MADISON, Wis., Feb. 22, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following virtual conferences and invited inves...

The Motley Fool - 2 weeks ago

These two companies have exciting long-term prospects.

Other stocks mentioned: GH
The Motley Fool - 2 weeks ago

The company reported disappointing Q4 results.

Zacks Investment Research - 2 weeks ago

Exact Sciences' (EXAS) legacy Screening business sees an uptick in revenues in Q4 earnings.

The Motley Fool - 2 weeks ago

Due to an accounting charge taken because of an acquisition, the company was deep in the red on the bottom line.

Benzinga - 2 weeks ago

Shares of Exact Sciences (NASDAQ:EXAS) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 59.46% over the past year to ($0.15), which...

PRNewsWire - 2 weeks ago

MADISON, Wis., Feb. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $466.3 million for the fourth quarter ended Dec. 31, 2020...

PRNewsWire - 2 weeks ago

MADISON, Wis., Feb. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has entered into an agreement to acquire Ashion Analytics, LLC (Ashion) from The Transl...

Benzinga - 2 weeks ago

Exact Sciences (NASDAQ:EXAS) announces its next round of earnings this Tuesday, February 16. Here is Benzinga's look at Exact Sciences's Q4 earnings report.

Zacks Investment Research - 3 weeks ago

Exact Sciences (EXAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research - 3 weeks ago

Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 3 weeks ago

Strength in Precision Oncology business is likely to have continued to aid Exact Sciences' (EXAS) performance in the fourth quarter of 2020 amid the coronavirus-led economic doldrums.

PRNewsWire - 1 month ago

MADISON, Wis., Feb. 1, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conferences and invited investors to p...

PRNewsWire - 1 month ago

MADISON, Wis., Feb. 1, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its fourth quarter 2020 financial results after the close of t...

Investors Business Daily - 1 month ago

Stock Indexes Hold Tough, But Leaders Struggle: Datadog, Exact Sciences, Freeport McMoRan In Focus

Stock indexes hold tough, but leaders struggle: Datadog, Exact Sciences, Freeport McMoRan in focus. Investor's Business Daily has been helping people invest smarter results by providing exclus...

Other stocks mentioned: DDOG, FCX
Seeking Alpha - 1 month ago

Multi-cancer screening is the holy grail for the test industry. Exact Sciences is pursuing it by acquiring complementary companies.

Zacks Investment Research - 1 month ago

Exact Sciences' (EXAS) strength in Screening revenue along with a robust COVID-19 testing arm are likely to have boosted the top line significantly.

PRNewsWire - 1 month ago

MADISON, Wis., Jan. 12, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) announced data published today in Cancer Prevention Research, a Journal of the American Association for Cancer ...

Zacks Investment Research - 1 month ago

Exact Sciences (EXAS) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

Benzinga - 1 month ago

Exact Sciences (NASDAQ: EXAS) shares are trading higher after the company issued fourth-quarter sales guidance above analyst estimates. Exact Sciences is a molecular diagnostics company focuse...

Other stocks mentioned: BIIB, LLY
The Motley Fool - 1 month ago

Investors really liked the company's sneak peek at its fourth-quarter results.

PRNewsWire - 1 month ago

MADISON, Wis., Jan. 10, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company expects to report revenue between $464.5 million and $467.5 million for the fo...

PRNewsWire - 2 months ago

MADISON, Wis., Jan. 5, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has completed its previously announced acquisition of Thrive Earlier Detection Corp. ("T...

PRNewsWire - 2 months ago

MADISON, Wis., Dec. 28, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conference and invited investors to p...

GuruFocus - 2 months ago

The S&P 500 saw its trailing 12-month real earnings per share (EPS) grow by approximately 1% on average every year over the past five years. The index's share price ($3,694.92 as of Monday) in...

Other stocks mentioned: HDB, HLF
Investors Business Daily - 2 months ago

Indexes Close Off Lows After Virus Scare; Nike, Generac, Exact Sciences In Focus

The stock market turned in resilient performance Monday, overcoming early fears of a new coronavirus strain in the U.K. Investor's Business Daily has been helping people invest smarter results...

Other stocks mentioned: GNRC, NKE
Investors Business Daily - 2 months ago

Nasdaq Hits Another High; Lululemon, DraftKings, Exact Sciences In Focus

The Dow, S&P 500 and Russell 2000 also hit new highs Thursday as more breakouts emerged. Investor's Business Daily has been helping people invest smarter results by providing exclusive stock l...

Other stocks mentioned: DKNG, LULU
PRNewsWire - 2 months ago

MADISON, Wis., Dec. 11, 2020 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced the presentation of new data at the virtual 2020 San Antonio Breast Cancer Symposium (SABCS) bu...

PRNewsWire - 3 months ago

MADISON, Wis., Nov. 23, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conference and invited investors to p...

Seeking Alpha - 3 months ago

Multiple companies are working on next-gen blood biopsies tech to detect cancer. The potential market size is big according to most estimates and analysts.

Other stocks mentioned: GH, ILMN, NTRA, PSNL
The Motley Fool - 3 months ago

Instead of investing in the company that would have made you a millionaire years ago, seek out the ones that have the potential from here.

Other stocks mentioned: DXCM
Investors Business Daily - 3 months ago

Stocks Rally To Cap Wild Week: Nio, Zoom Video Flash Sell Signals; Exact Sciences Trades Bullishly

Stocks rally to cap wild week: Nio, Zoom Video flash sell signals; Exact Sciences trades bullishly. Investor's Business Daily has been helping people invest smarter results by providing exclus...

Other stocks mentioned: NIO, ZM
The Motley Fool - 3 months ago

A solid third quarter plus an acquisition to drive future growth has investors giddy.

Zacks Investment Research - 4 months ago

Technology won't always be on top. There's a bunch of budding industries that could prove to be winners over the next 5 years.

Other stocks mentioned: INMD, QQQ, VCEL, XLK
Zacks Investment Research - 4 months ago

Exact Sciences' (EXAS) legacy screening business sees a decline in revenues in Q3 earnings.

PRNewsWire - 4 months ago

MADISON, Wis., Nov. 2, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conferences and invited investors to p...

Seeking Alpha - 4 months ago

Exact Sciences Corporation (EXAS) CEO Kevin Conroy on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 4 months ago

PRESS RELEASE: REGULATORY INFORMATION – INSIDE INFORMATION

PRNewsWire - 4 months ago

MADISON, Wis., Oct. 27, 2020 /PRNewswire/ -- The United States Preventive Services Task Force (USPSTF) today released draft updated colorectal cancer screening guidelines recommending that scr...

Business Insider - 4 months ago

Exact Sciences soared as much as 33% on Tuesday to record highs after the diagnostics company said it would acquire Thrive Earlier Detection for up to $2.15 billion in a stock and cash deal. T...

The Motley Fool - 4 months ago

Solid earnings and a smart acquisition have investors hitting the buy button.

Benzinga - 4 months ago

Shares of cancer screening and diagnostics company EXACT Sciences Corporation (NASDAQ: EXAS) were rallying to a record high Tuesday after it announced two M&A transactions and third-quarter re...

InvestorPlace - 4 months ago

Exact Sciences (EXAS) stock was flying high on Tuesday following a flurry of news from the molecular diagnostics company. The post Exact Sciences News: Why EXAS Stock Is Shooting 18% Higher To...

Zacks Investment Research - 4 months ago

Exact Sciences (EXAS) delivered earnings and revenue surprises of 29.41% and 16.35%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the st...

Market Watch - 4 months ago

Exact Sciences Corp. said Tuesday it has agreed to acquire Thrive Earlier Detection Corp. in a cash and stock deal worth up to $2.15 billion. Thrive Earlier is a health care company that aims ...

PRNewsWire - 4 months ago

MADISON, Wis., Oct. 27, 2020 /PRNewswire/ -- Exact Sciences Corporation (Nasdaq: EXAS) today announced the entry into agreements to sell an aggregate of 8,605,483 shares (the "Shares") of its ...

PRNewsWire - 4 months ago

MADISON, Wis., Oct. 27, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $408.4 million for the third quarter ended September 30, ...

Insider Monkey - 4 months ago

Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend mi...

Zacks Investment Research - 4 months ago

Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 4 months ago

MADISON, Wis., Oct. 12, 2020 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced the introduction of the Oncotype MAP™ Pan-Cancer Tissue test for patients with advanced, metast...

About EXAS

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX ... [Read more...]

Industry
Diagnostics & Research
Founded
1995
CEO
Kevin Conroy
Employees
4,800
Stock Exchange
NASDAQ
Ticker Symbol
EXAS
Full Company Profile

Financial Performance

In 2020, Exact Sciences's revenue was $1.49 billion, an increase of 70.19% compared to the previous year's $876.29 million. Losses were -$848.53 million, 910.2% more than in 2019.

Financial Statements

Analyst Forecasts

According to 16 analysts, the average rating for Exact Sciences stock is "Strong Buy." The 12-month stock price forecast is 173.00, which is an increase of 42.22% from the latest price.

Price Target
$173.00
(42.22% upside)
Analyst Consensus: Strong Buy